AR065554A1 - Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas. - Google Patents
Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR065554A1 AR065554A1 ARP080100850A ARP080100850A AR065554A1 AR 065554 A1 AR065554 A1 AR 065554A1 AR P080100850 A ARP080100850 A AR P080100850A AR P080100850 A ARP080100850 A AR P080100850A AR 065554 A1 AR065554 A1 AR 065554A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline salt
- pharmaceutical compositions
- processes
- azabiciclo
- octano
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Composiciones farmacéuticas que comprenden dichas formas de sal cristalina, métodos de uso de dichas formas de sal cristalina para tratar enfermedades asociadas con la actividad del receptor opioide mu, y los procesos utiles para preparar dichasformas de sal cristalina. Reivindicacion 1: Una forma de sal cristalina, caracterizada porque es la sal sulfato de 3-endo-(8-{2-[ciclohexilmetil-((S)-2,3-dihidroxi-propionil)amino]etil}-8-aza-biciclo[3,2,1]oct-3-il)benzamida o un solvato de esta. Reivindicacion 3: La forma de sal cristalina de la reivindicacion 2, caracterizada por un patron de difraccion de polvo de rayos X que tiene dos o más picos de difraccion con valores 2theta seleccionados entre 6,58 +- 0,20, 7,52 +- 0,20, 9,35 +- 0,20, 14,79 +- 0,20, 16,01 +- 0,20, 17,45 +- 0,20, 17,99 +- 020, 18,72 +- 0,20, 19.76 +- 0,20, 21,11 +- 0,20, 22,07 +- 0,20, 23,18 +- 0,20, 23,74 +- 0,20, 24,56 +- 0,20, 25,73 +- 0,20, 26,45 +- 0,20, 27,86 +- 0,20, 28,31 +- 0,20, 29,54 +- 0,20, 30,59 +- 0,20, 31,58+- 0,20, 33,89 +- 0,20 y 36,02 +- 0,20.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90409007P | 2007-02-28 | 2007-02-28 | |
PCT/US2008/002583 WO2008106159A1 (en) | 2007-02-28 | 2008-02-27 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065554A1 true AR065554A1 (es) | 2009-06-17 |
Family
ID=39620376
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100850A AR065554A1 (es) | 2007-02-28 | 2008-02-28 | Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas. |
ARP170102183A AR109224A2 (es) | 2007-02-28 | 2017-07-31 | Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102183A AR109224A2 (es) | 2007-02-28 | 2017-07-31 | Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento |
Country Status (27)
Country | Link |
---|---|
US (7) | US7943772B2 (es) |
EP (1) | EP2132204B1 (es) |
JP (2) | JP5512289B2 (es) |
KR (1) | KR101480530B1 (es) |
CN (1) | CN101616916B (es) |
AR (2) | AR065554A1 (es) |
AU (1) | AU2008219615B2 (es) |
BR (1) | BRPI0807974B8 (es) |
CA (1) | CA2678073C (es) |
CL (1) | CL2008000573A1 (es) |
CO (1) | CO6220856A2 (es) |
CY (1) | CY1115077T1 (es) |
DK (1) | DK2132204T3 (es) |
ES (1) | ES2402031T3 (es) |
HK (1) | HK1139399A1 (es) |
HR (1) | HRP20130193T1 (es) |
IL (1) | IL200131A (es) |
MX (1) | MX2009009141A (es) |
MY (1) | MY148318A (es) |
NZ (1) | NZ578871A (es) |
PL (1) | PL2132204T3 (es) |
PT (1) | PT2132204E (es) |
RU (1) | RU2458061C2 (es) |
SI (1) | SI2132204T1 (es) |
TW (1) | TWI409067B (es) |
WO (1) | WO2008106159A1 (es) |
ZA (1) | ZA200905832B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY145633A (en) * | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
TWI409067B (zh) * | 2007-02-28 | 2013-09-21 | Theravance Inc | 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型 |
TWI415850B (zh) * | 2007-07-20 | 2013-11-21 | Theravance Inc | 製備mu類鴉片受體拮抗劑之中間物的方法 |
EP2185553B1 (en) * | 2007-08-27 | 2012-06-27 | Theravance, Inc. | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
ATE502939T1 (de) * | 2007-08-27 | 2011-04-15 | Theravance Inc | Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten |
TWI423801B (zh) * | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之8-氮雜雙環〔3.2.1〕辛基-2-羥基苯甲醯胺化合物 |
EP2195313B1 (en) * | 2007-08-27 | 2014-04-02 | Theravance, Inc. | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
BR112012006069A8 (pt) * | 2009-09-18 | 2017-10-10 | Adolor Corp | Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto |
SI3277278T1 (sl) * | 2015-04-02 | 2020-04-30 | Theravance Biopharma R&D Ip, Llc | Kombinacijska odmerna oblika mu-opioidnega receptorskega antagonista in opioidnega sredstva |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5159081A (en) * | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
US6900228B1 (en) * | 1998-03-10 | 2005-05-31 | Research Triangle Institute | Opiate compounds, methods of making and methods of use |
GB9810671D0 (en) * | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
TWI244481B (en) * | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
GB9912410D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
US6469030B2 (en) * | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
US6467084B1 (en) * | 1999-12-16 | 2002-10-15 | Emware, Inc. | Systems and methods for reprogramming an embedded device with program code using relocatable program code |
AU2001241676A1 (en) | 2000-03-03 | 2001-09-17 | Ortho-Mcneil Pharmaceutical, Inc. | 3-(diarylmethylene)-8-azabicyclo(3.2.1)octane derivatives |
US20020025948A1 (en) * | 2000-06-23 | 2002-02-28 | Banks Bernard Joseph | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
PT1440059E (pt) * | 2001-10-22 | 2008-05-16 | Pfizer Prod Inc | Derivados do 3-azabiciclo(3.1.0)hexano como antagonistas de receptores opióides |
US7381721B2 (en) * | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
US7056930B2 (en) | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
EP1615894A2 (en) * | 2003-04-14 | 2006-01-18 | Pfizer Products Inc. | 3-azabicyclo 3.2.1 octane derivatives |
US20040204453A1 (en) * | 2003-04-14 | 2004-10-14 | Pfizer Inc | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors |
EP1615920A1 (en) | 2003-04-15 | 2006-01-18 | Pfizer Products Inc. | 3-benzhydrylidene-8-aza-bicyclo [3.2.1] octane derivatives with opioid receptor activity |
US6992090B2 (en) * | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
WO2005075472A1 (en) | 2004-02-03 | 2005-08-18 | Janssen Pharmaceutica, N.V. | 3-(diheteroarylnethylene)-8-azabicyclo[3.2.1]octane and 3-(aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives |
US7087749B2 (en) * | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
US20100284960A1 (en) | 2006-11-07 | 2010-11-11 | Nektar Therapeutics Al, Corporation | Dosage Forms and Co-Administration of Opioid Agonist and Opioid Antagonist |
TWI409067B (zh) * | 2007-02-28 | 2013-09-21 | Theravance Inc | 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型 |
-
2008
- 2008-02-15 TW TW097105472A patent/TWI409067B/zh active
- 2008-02-25 CL CL200800573A patent/CL2008000573A1/es unknown
- 2008-02-27 MY MYPI20093401A patent/MY148318A/en unknown
- 2008-02-27 DK DK08726162.4T patent/DK2132204T3/da active
- 2008-02-27 NZ NZ578871A patent/NZ578871A/en not_active IP Right Cessation
- 2008-02-27 EP EP08726162A patent/EP2132204B1/en active Active
- 2008-02-27 PT PT87261624T patent/PT2132204E/pt unknown
- 2008-02-27 WO PCT/US2008/002583 patent/WO2008106159A1/en active Application Filing
- 2008-02-27 BR BRPI0807974A patent/BRPI0807974B8/pt active IP Right Grant
- 2008-02-27 PL PL08726162T patent/PL2132204T3/pl unknown
- 2008-02-27 SI SI200830928T patent/SI2132204T1/sl unknown
- 2008-02-27 JP JP2009551709A patent/JP5512289B2/ja active Active
- 2008-02-27 AU AU2008219615A patent/AU2008219615B2/en active Active
- 2008-02-27 RU RU2009135834/04A patent/RU2458061C2/ru active
- 2008-02-27 CA CA2678073A patent/CA2678073C/en active Active
- 2008-02-27 ES ES08726162T patent/ES2402031T3/es active Active
- 2008-02-27 KR KR1020097020094A patent/KR101480530B1/ko active IP Right Grant
- 2008-02-27 CN CN2008800059690A patent/CN101616916B/zh active Active
- 2008-02-27 MX MX2009009141A patent/MX2009009141A/es active IP Right Grant
- 2008-02-27 US US12/072,534 patent/US7943772B2/en active Active
- 2008-02-28 AR ARP080100850A patent/AR065554A1/es not_active Application Discontinuation
-
2009
- 2009-07-29 IL IL200131A patent/IL200131A/en active IP Right Grant
- 2009-08-21 ZA ZA200905832A patent/ZA200905832B/xx unknown
- 2009-08-26 CO CO09089674A patent/CO6220856A2/es active IP Right Grant
-
2010
- 2010-06-15 HK HK10106008.5A patent/HK1139399A1/xx unknown
-
2011
- 2011-04-06 US US13/081,162 patent/US8247555B2/en active Active
-
2012
- 2012-07-17 US US13/550,781 patent/US8536335B2/en active Active
-
2013
- 2013-03-05 HR HRP20130193AT patent/HRP20130193T1/hr unknown
- 2013-04-08 CY CY20131100293T patent/CY1115077T1/el unknown
- 2013-05-10 JP JP2013099851A patent/JP2013151564A/ja not_active Withdrawn
- 2013-08-13 US US13/965,691 patent/US8816091B2/en active Active
-
2014
- 2014-07-16 US US14/333,003 patent/US9290491B2/en active Active
-
2016
- 2016-02-10 US US15/040,191 patent/US9949963B2/en active Active
-
2017
- 2017-07-31 AR ARP170102183A patent/AR109224A2/es unknown
-
2018
- 2018-03-13 US US15/919,678 patent/US10426766B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065554A1 (es) | Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas. | |
AR106702A2 (es) | Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento | |
UY29781A1 (es) | Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos | |
UY27720A1 (es) | Aroilpiridinonas monocíclicas, | |
AR065083A1 (es) | Hepcidina, antagonistas de la hepcidina y metodos de uso | |
CL2013002341A1 (es) | Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros | |
CL2007003187A1 (es) | Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de | |
AR063347A1 (es) | Formas cristalinas de docetaxel y proceso para su preparacion | |
ECSP10010008A (es) | (2s,3r)-n-(2-((3-piridinil)metil)-azabiciclo[2.2.2]oct-3- il)benzofuran-2-carboxamida, formas de sal novedosas, y métodos de uso de los mismos | |
ECSP088904A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
AR053208A1 (es) | Forma cristalina de un compuesto de quinolinona carboxamida | |
AR082804A1 (es) | Formas cristalinas de un inhibidor del factor xa | |
PE20121179A1 (es) | Forma cristalina de hemifumarato de alisquireno | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
CL2007003609A1 (es) | Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion | |
BR112013009117A2 (pt) | sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo. | |
AR077203A1 (es) | Forma polimorfica d del acetato de bazedoxifeno, composiciones farmaceuticas que la contienen metodo para prepararla y uso del mismo para tratar enfermedades mediadas por moduladores selectivos de receptores estrogenicos (serms) | |
BRPI0815493A2 (pt) | Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto. | |
BRPI0606199A2 (pt) | hidrocloreto de rimonabant, processo para a preparação de um hidrocloreto de rimonabant, composição farmacêutica, forma de dosagem farmacêutica, uso de um hidrocloreto de rimonabant e método de tratamento | |
AR124497A2 (es) | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica | |
UY27850A1 (es) | Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen | |
BRPI0914912A2 (pt) | processo para a preparação de um composto, e de um inibidor de mtor quinase, sal de fumarato, composição farmacêutica, uso de um sal de fumarato, e, métodos para produzir um efeito inibitório mtor, e para produzir um efeito anti-câncer em um animal de sangue quente | |
PE20130212A1 (es) | Formas polimorficas de st-246 y metodos de preparacion | |
CL2007003346A1 (es) | Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |